Reimagining Drug-Deliverywith Microfluidic Engineering
Inventage Lab pioneers microfluidic-based drug-delivery platforms that enable exceptional particle uniformity, precise and tunable release kinetics, and seamless scalability from R&D to full commercial manufacturing. By powering long-acting injectables, high-concentration biologics, and next-generation nucleic-acid delivery, we redefine therapeutic performance and expand the boundaries of pharmaceutical innovation.
Platform
Introducing Inventage Lab Technology
IVL-DrugFluidic®
DrugFluidic® is a long-acting injectable platform based on microfluidic technology. It precisely controls the size, uniformity, and release rate of microparticles to achieve stable and predictable drug release. Depending on the potency and dosage of the drug, dosing intervals can be flexibly designed from 1 to 6 months. By scaling up the established formulation conditions through multi-channel parallelization, we ensure consistent quality and high scale-up reproducibility from research to commercial production. This platform is applicable to various active ingredients, including small molecules and peptides, contributing to improved patient convenience and treatment compliance in chronic disease management.
IVL-BioFluidic™
BioFluidic™ is a formulation platform that enables ultra-high concentration biologics with low viscosity and high stability through microfluidic-based processes. By controlling high-molecular-weight biologics like proteins and antibodies in uniform microstructures, it minimizes aggregation and stabilizes physical properties. This offers the possibility of converting high-dose formulations that previously depended on intravenous injection to subcutaneous and self-injection. It improves dosing convenience and treatment accessibility, while expanding product competitiveness and lifecycle value through differentiated formulation strategies.
IVL-GeneFluidic®
IVL-GeneFluidic® is an LNP (Lipid Nanoparticle)–based delivery platform designed for the development of mRNA vaccines and gene therapeutics. Utilizing continuous microfluidic mixing technology, it enables the production of highly reproducible, high-quality nanoparticles from lab scale to GMP scale. Through precise control of lipid composition and uniform particle formation, it allows optimized formulation design for various genetic materials. It provides core infrastructure for mRNA vaccines and gene therapeutics through large-scale GMP continuous processing.
R&D Pipeline
Inventage Lab Pipeline
Inventage Lab's R&D pipeline consists of various development programs from early to late stages, aiming to address unmet medical needs in intractable and chronic diseases. All candidates are based on our proprietary IVL-DrugFluidic®, IVL-BioFluidic™, and IVL-GeneFluidic® platforms, designed to significantly improve drug delivery efficiency and duration. We are also accelerating the development of innovative therapeutics through collaboration with domestic and international pharmaceutical companies.
